Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze EXAS stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate EXAS investment potential.

What is EXAS stock price today?

Get real-time EXAS stock price, historical data, and price charts on Financhill. Track EXAS performance with our advanced analysis tools.

Is EXAS a good investment?

Evaluate EXAS investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy EXAS stock?

To buy EXAS stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of EXAS?

View detailed market capitalization data and company valuation metrics for EXAS on our comprehensive analysis page.

What is the P/E ratio of EXAS?

Use our fundamental analysis tools to view EXAS P/E ratio and compare valuation metrics with industry peers.

What are EXAS earnings?

View EXAS earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

EXACT Sciences Corp. 10K Form

Buy

EXAS
EXACT Sciences Corp.

Last Price:

$101.11

Seasonality Move:

9.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-08	10Q	EXAS/EXACT Sciences Corp. Quarterly
2023-11-01	10Q	EXAS/EXACT Sciences Corp. Quarterly
2023-08-01	10Q	EXAS/EXACT Sciences Corp. Quarterly
2023-05-09	10Q	EXAS/EXACT Sciences Corp. Quarterly
2022-11-03	10Q	EXAS/EXACT Sciences Corp. Quarterly
2022-08-02	10Q	EXAS/EXACT Sciences Corp. Quarterly

Receive EXAS News And Ratings

See the #1 stock for the next 7 days that we like better than EXAS

EXAS Financial Statistics

Sales & Book Value

Annual Sales:	$2.8B
Cash Flow:	$190M
Price / Cash Flow:	65.02
Annual Sales:	$13.20
Price / Book:	7.67

Profitability

EPS (TTM):	-5.31720
Net Income (TTM):	$-986.6M
Gross Margin:	$1.9B
Return on Equity:	-38%
Return on Assets:	-16.27%

EXACT Sciences Corp. Earnings Forecast

Key EXACT Sciences Corp. Financial Ratios

The Gross Profit Margin over the past 28 years for EXAS is 69.55%.
The Selling, General & Administrative Expenses for EXAS have been equal to 60.75% of Gross Profit Margin.
The Research & Development expenses have been 15.63% of Revenue.
The Net Earning history of EXAS is -37.29% of Total Revenues.
Per Share Earnings over the last 28 years have been positive in 14 years.

EXACT Sciences Corp. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	EXAS
CUSIP:	30063P
Website:	exactsciences.com

Debt

Debt-to-Equity Ratio:	1.01
Current Ratio:	2.72
Quick Ratio:	2.24

Price-to-Earnings

Trailing P/E Ratio:	0
Forward P/E Ratio:	90.57

EXAS Technical Analysis vs Fundamental Analysis

Buy

EXACT Sciences Corp. (EXAS) is a Buy

Is EXACT Sciences Corp. a Buy or a Sell?

EXACT Sciences Corp. stock is rated a Buy

The current EXACT Sciences Corp. [EXAS] share price is $101.25. The Score for EXAS is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.